Achillon Pharmaceuticals
Seite 1 von 1 Neuester Beitrag: 24.04.21 23:19 | ||||
| Eröffnet am: | 17.02.09 12:52 | von: macos | Anzahl Beiträge: | 17 |
| Neuester Beitrag: | 24.04.21 23:19 | von: Johannahrlna | Leser gesamt: | 8.753 |
| Forum: | Hot-Stocks | Leser heute: | 1 | |
| Bewertet mit: |  | |||
http://finance.aol.com/company/...nc/achn/nas/institutional-ownership
Magere Pipe 1 mittel gegen HIV in Phase 2 und Mittel gegen Hepatitis C mit Partner Gilead in der Präklinik!
27 Millionen Shares und ca 40 mio Cash?
Bin mit ner Schnupperposi drin!
Gruss Macos
Product Pipeline
PRODUCT PIPELINEFOR HCV INFECTION
ACH-1095/GS-9525ACH-1625FOR BACTERIAL INFECTION
ACH-702FOR HIV INFECTION
ELVUCITABINEACH-1095/GS-9525 is a novel-mechanism NS4A antagonist being developed by Achillion and Gilead for the $4B HCV market.
ACH-1625 is a potent inhibitor of HCV NS3 protease with good toxicology, a unique PK profile, and strong potential for once-daily dosing.
ACH-702 is a
broad-spectrum bactericidal orally available compound for $2B serious bacterial infections market with a novel target profile against bacterial DNA replication enzymes.
ELVUCITABINE is a HIV nucleoside for the $3.7B NRTI market that has demonstrated potent antiviral activity, including against HIV strains resistant to other NRTIs.LEARN ABOUT OUR CLINICAL TRIALS. GO TO ClinicalTrials.gov
Achillion's broad drug development pipeline focuses on the discovery and development of drugs to treat diseases caused by viruses and bacteria, particularly the most challenging of these infectious diseases HIV, hepatitis and resistant bacterial infections. The Company's drug discovery expertise embodies an innovative program-based approach to identifying new infectious disease targets and designing small molecule drugs to attack these targets.
The Company's lead candidate is elvucitabine, a novel nucleoside analog currently being evaluated in Phase 2 studies for the treatment of patients with HIV. Achillion believes that elvucitabine addresses several of the limitations of currently marketed therapies and is an ideal candidate for partnerships around combination preparations and/or geographic commercialization alliances. Achillion is also developing ACH-702, its candidate for the treatment of serious, hospital-based bacterial infections, and multiple NS4A antagonists, a unique class of candidates for the treatment of hepatitis C, which are partnered with Gilead Sciences. Both ACH-702 and the NS4A antagonists were discovered through Achillion's own proprietary internal drug discovery efforts.
Gilead ist mit ca 5 % beteiligt!
aus 2004
Gilead and Achillion Announce Collaboration for the Development and Commercialization of Achillion's Hepatitis C Compounds
Foster City, CA and New Haven, CT, November 29, 2004 — Gilead Sciences (Nasdaq: GILD) and Achillion Pharmaceuticals today announced that the companies have signed an exclusive agreement granting Gilead worldwide rights for the research, development and commercialization of certain Achillion compounds for the treatment of infection with the hepatitis C virus (HCV). The compounds, small molecule inhibitors of HCV replication, are believed to act through a novel mechanism of action involving HCV protease. In this collaboration, Achillion will continue development of the compounds, according to a mutually agreed upon development plan, through completion of a proof-of-concept clinical study in HCV-infected patients. Following the proof-of-concept study, Gilead will assume full responsibilities and costs associated with development and commercialization for compounds warranting further development.
Under the terms of the agreement, Gilead will pay to Achillion a $5 million upfront license payment and will purchase $5 million of equity. In addition, Gilead will provide partial funding through the completion of the proof-of-concept study. Achillion could also earn milestone payments in excess of $100 million under the agreement, based upon the achievement of certain development, regulatory and commercial goals, and will have the option to participate in U.S. commercialization efforts for any future products arising from this collaboration. Achillion’s milestone payments could increase substantially assuming progress is made on multiple related compounds. Gilead will receive exclusive worldwide license rights and will pay Achillion a royalty on net sales of future products arising from the collaboration.
“Gilead and Achillion share a commitment to developing advanced therapeutics for the treatment of significant unmet medical needs, such as HCV,” said John C. Martin, PhD, President and Chief Executive Officer of Gilead Sciences. “Achillion’s drug discovery and development expertise, particularly in identifying unique drug targets with the potential to address drug resistance, makes the company an ideal partner for Gilead. We believe Achillion’s compounds work through a novel mechanism, making them excellent potential candidates for HCV combination therapy regimens. We look forward to collaborating with Achillion to rapidly advance new compounds for the treatment of HCV.”
“This collaboration highlights the strength of Achillion’s discovery and development capabilities and its ability not only to create important new compounds for treatment of life-threatening infectious diseases, but also to advance such compounds into clinical proof-of-concept studies. Gilead’s commercial franchise and expertise in antiviral drug development has made the company our strongly preferred partner to advance and commercialize compounds from our exciting HCV program,” stated Michael Kishbauch, Chief Executive Officer of Achillion. “We believe that this agreement provides an important catalyst to this program while also freeing up resources to advance our own HIV and antibacterial programs.”
Hepatitis C is a viral liver disease, caused by infection with the hepatitis C virus. Globally, more than 170 million people have chronic hepatitis C. About 3 million Americans are now estimated to be chronically infected with the hepatitis C virus. HCV is a leading cause of cirrhosis, a common cause of hepatocellular carcinoma, and is the leading cause of liver transplantation in the United States.
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases worldwide. The company has seven marketed products, and focuses its research and clinical programs on anti-infectives. Headquartered in Foster City, CA, Gilead has operations in North America, Europe and Australia.
About Achillion
Achillion is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. The company’s proven discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused on solutions for the most challenging problems in infectious disease – HIV, hepatitis and resistant bacterial infections.
11:16 09.03.09
Endingen (aktiencheck.de AG) - Nach Meinung der Experten von "Global Biotech Investing" schlummert in der Achillion Pharmaceuticals-Aktie (Profil) ein gewaltiges Potenzial.
Die Biotech-Gesellschaft sei Ende 2006 zu Kursen von 14 USD an die Börse gekommen. Inzwischen habe sich die Marktkapitalisierung von damals 330 auf 25 Mio. USD reduziert. Dieser Kursverfall sei für die Analysten von Think Equity Partners überzogen, die Ende Januar die Coverage für die Aktie mit einem "buy"-Rating und einem Kursziel von 2,50 USD gestartet hätten. So seien ihrer Meinung nach im gegenwärtigen Kursniveau keinerlei Erfolge aus den vielversprechenden Forschungsreihen berücksichtigt.
Aktuell verfolge Achillion Pharmaceuticals zwei Forschungsprogramme für Hepatitis C-Präparate. Diese sollten noch im aktuellen Quartal die klinische Phase der Entwicklung erreichen. Bezüglich des Wirkstoffs ACH-1095 sei sogar eine Zusammenarbeit mit Gilead Sciences vereinbart worden, wodurch Achillion Pharmaceuticals Meilensteinzahlungen von bis zu 155 Mio. USD erhalten könnte. Dies zeige, dass man die Gesellschaft in den nächsten Jahren durchaus auf der Rechnung haben sollte.
Anleger, die die Erholungsrally mitreiten möchten, sollen mit einer kleinen spekulativen Position auf die Aktie von Achillion Pharmaceuticals aufspringen, raten die Experten von "Global Biotech Investing". (Ausgabe 05 vom 09.03.2009)
(09.03.2009/ac/a/a)
Receives Novel Mechanism of Action Claims as Inhibitor of Viral Replication
NEW HAVEN, Conn., Apr 16, 2009 (GlobeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that the U.S. Patent & Trademark Office has granted Achillion U.S. Patent No. 7,476,686 related to the Achillion NS4A antagonists to treat the hepatitis C virus (HCV). This new patent, entitled "Substituted Aryl Thioureas and related compounds; inhibitors of viral replication," includes novel mechanism of action claims and expires in 2025.
"In addition to securing intellectual property protection for these novel compounds, we believe this key patent grant underscores Achillion's strength in discovery and development and provides a cornerstone of our patent portfolio for novel NS4A antagonists," commented Michael D. Kishbauch, Achillion's President and Chief Executive Officer. "In partnership with Gilead Sciences, the NS4A program continues to advance toward human clinical trials, which we hope to commence in 2009."
In collaboration with Gilead Sciences, Achillion is evaluating a series of product candidates that specifically recognize a new HCV target, NS4A. As a result of their novel mechanism of action, broad potency against HCV, potential for oral administration and demonstrated lack of cross resistance, Achillion believes there could be significant market opportunity for its compounds in this area of unmet medical need.
About NS4A Antagonists
Based upon extensive virology and biochemistry studies, the novel mechanism of action of Achillion's NS4A antagonists involves targeting the NS4A protein of HCV. Inhibiting this target prevents the formation of a functional replicase complex, a necessary step in viral replication that occurs before copying the viral RNA genome. Achillion believes this unique mechanism may contribute to the lack of cross resistance between its compounds and other HCV inhibitors.
About HCV
The hepatitis C virus (HCV) is the most common cause of viral hepatitis, which is an inflammation of the liver. It is currently estimated that more than 170 million people are infected with HCV worldwide and The American Association of Liver Disease estimates that up to 80% of individuals become chronically infected following exposure. If left untreated, chronic hepatitis can lead to permanent liver damage, which can result in the development of liver cancer, liver failure or death. Few therapeutic options currently exist for the treatment of HCV infection. The current standard of care is limited by its specificity for certain types of HCV, significant side-effect profile, injectable route of administration and high cost.
About Achillion
Achillion is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. Achillion's proven discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused on solutions for the most challenging problems in infectious disease -- hepatitis, resistant bacterial infections and HIV. For more information on Achillion Pharmaceuticals, please visit www.achillion.com or call 1-203-624-7000.
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including statements with respect to Achillion's expectations regarding the enforceability of patents, timing and duration of clinical trials and Achillion's expectations regarding the release of data from ongoing clinical trials. Among the factors that could cause actual results to differ materially from those indicated by such forward-looking statements are: unexpected regulatory actions or delays; uncertainties relating to results of clinical trials, including additional data relating to ongoing clinical trials, and Achillion's ability to obtain additional funding required to conduct its research, development and commercialization activities along with Achillion's ability to attract and develop potential collaboration relationships. These and other risks are described in the reports filed by Achillion with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2008.
All forward-looking statements reflect Achillion's expectations only as of the date of this release and should not be relied upon as reflecting Achillion's views, expectations or beliefs at any date subsequent to the date of this release. Achillion anticipates that subsequent events and developments may cause these views, expectations and beliefs to change. However, while Achillion may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.
ACHN-G
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: Achillion Pharmaceuticals, Inc
Achillion Pharmaceuticals, Inc.
Mary Kay Fenton
(203) 624-7000
mfenton@achillion.com
Lippert/Heilshorn & Associates, Inc.
Investors:
Anne Marie Fields
(212) 838-3777
afields@lhai.com
Bruce Voss
(310) 691-7100
bvoss@lhai.com
Media:
Jules Abraham
(212) 838-3777
jabraham@lhai.com
(C) Copyright 2009 GlobeNewswire, Inc. All rights reserved.
News Provided by COMTEX
http://bigcharts.marketwatch.com/interchart/...;sid=2445371&time=
On Friday May 15, 2009, 7:00 am EDT
Buzz up! Print Related:Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., May 15, 2009 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (NasdaqGM:ACHN - News), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the three months ended March 31, 2009. For the first quarter of 2009, the Company reported a net loss of $6.7 million, compared to a net loss of $6.0 million in the same quarter last year. Cash and cash equivalents and marketable securities at March 31, 2009 were $27.1 million.
Related Quotes
Symbol Price Change
ACHN 1.70 -0.35
{"s" : "achn","k" : "c10,l10,p20,t10","o" : "","j" : ""} The Company also announced that it has entered discussions with its collaboration partner, Gilead Sciences, Inc. (NasdaqGS:GILD - News), regarding a proposal for restructuring their existing license and collaboration agreement. Achillion has proposed that it continue to develop ACH-1095, also known as GS 9525, with retention of certain rights by Gilead. At the same time, the parties would jointly continue to advance additional compounds also operating by Achillion's proprietary NS4A mechanism of action. Achillion and Gilead have arrived at different opinions on the appropriate further progression of ACH-1095, based on their respective scientific assessments of the therapeutic index for ACH-1095 from various preclinical studies. Gilead indicated that it does not intend to initiate clinical development of GS 9525, while Achillion believes that the compound should be advanced.
``Clinical and preclinical data suggest that drugs such as ACH-1095 may provide important treatment advantages for patients with HCV, and we see significant opportunities for ACH-1095 to advance, ultimately in combination with other direct acting anti-virals,'' said Michael Kishbauch, President and CEO of Achillion. ``Our experienced clinical, regulatory and scientific team looks forward to continued development of ACH-1095 and will request a pre-IND meeting to discuss the compound's development path with the FDA. We understand the compound may no longer fit the particular profile desired by Gilead, given its current strategic priorities.
``We also anticipate the first-in-human clinical dosing of our HCV protease inhibitor, ACH-1625, later this quarter,'' Kishbauch continued. With its unique pharmacokinetics, suggestive of once daily dosing, good safety profile, and proven mechanism of action, we believe ACH-1625 has potential to become a best-in-class protease inhibitor for HCV infection.``
First quarter results
For the first quarter of 2009, the Company reported a net loss of $6.7 million, compared to a net loss of $6.0 million in the first quarter of 2008. Cash and cash equivalents and marketable securities at March 31, 2009 were $27.1 million.
Revenue for the three months ended March 31, 2009 was negative $293,000, compared to revenue of $627,000 in the three months ended March 31, 2008. The negative revenue reflects an excess of amounts billed by Gilead to Achillion under the collaboration, compared to amounts billed by Achillion to Gilead. Under the collaboration, costs are shared equally between the parties. In addition, for the three months ended March 31, 2009, Achillion did not recognize any revenue related to amortization of its up-front, milestone and FTE payments previously received under its collaboration with Gilead, as at this time the program does not have a lead compound upon which it can accurately estimate its future performance obligations.
Research and development expenses were $4.8 million in the first quarter of 2009, compared to $5.0 million for the same period of 2008. Research and development expenses were primarily related to costs incurred from late stage preclinical assessment of the Company's two HCV compounds, and to a lesser extent, from ongoing clinical trials for elvucitabine for HIV.
For the three months ended March 31, 2009, general and administrative expenses totaled $1.6 million, down slightly from $1.7 million for the same period in 2008.
About Achillion
Achillion is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. The company's proven discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused on solutions for the most challenging problems in infectious disease -- hepatitis, resistant bacterial infections and HIV. For more information on Achillion Pharmaceuticals, please visit the company's web site at http://www.achillion.com or call Achillion at 1-203-624-7000.
Achieves 3.94 log10 Reduction in HCV RNA With Continued Safety and Tolerability
http://finance.yahoo.com/news/...tive-pz-3012910255.html?x=0&.v=1
Second Dosing Cohort Achieves 4.25log10 Viral Load Reduction With Continued Safety and Tolerability
http://finance.yahoo.com/news/...nces-pz-3158812622.html?x=0&.v=1
http://online.wsj.com/article/BT-CO-20130221-705332.html#
Optionen
| Boardmail an "brunneta" |
Wertpapier: Achillion Pharmaceutica |
Optionen
| Boardmail an "butzerle" |
Wertpapier: Achillion Pharmaceutica |
Optionen
| Boardmail an "vinternet" |
Wertpapier: Achillion Pharmaceutica |
Optionen
| Boardmail an "vinternet" |
Wertpapier: Achillion Pharmaceutica |
Angehängte Grafik:
ach.jpg (verkleinert auf 97%)
ach.jpg (verkleinert auf 97%)
Optionen
| Boardmail an "vinternet" |
Wertpapier: Achillion Pharmaceutica |